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Meta-analysisIntroduction: Advanced heart failure is a malignant disease characterized by a debilitating late course, with
increasingly frequent hospitalisations and high rate of mortality.
Levosimendan, an inodilator developed for the treatment of acutely decompensated chronic heart failure, has
been recently proposed also as a repetitive treatment of advanced heart failure.
Several studies on the use of levosimendan in this settings report mortality data. Independent meta-analyses on
the effect on mortality of repetitive or intermittent levosimendan administration in advanced heart failure has
been published but were criticized in regard to the selection of the studies. Meanwhile new data became avail-
able. We therefore updated the selection of studies and re-analyzed all the available data.
Methods & results: Data from seven randomized trial and a total of 438 adult patients using intermittent
levosimendan in a cardiological setting were included in the present analysis. The average follow-up period
was 8 ± 3.8 months. The use of levosimendan was associated with a signiﬁcant reduction in mortality at the
longest follow-up available [41 of 257 (16%) in the levosimendan group vs. 39 of 181 (21.5%) in the control
arm, OR = 0.54 (95% CI 0.32–0.91), p for effect = 0.02, p for heterogeneity = 0.64, I2 = 0%].
Conclusions: The updated results suggest that repetitive or intermittent levosimendan administration in
advanced heart failure is associated with a signiﬁcant reduction in mortality at the longest follow-up available.
There is therefore a strong rationale for a randomized clinical trial with adequate power on mortality.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Advanced heart failure (AdHF) is one of the presentations of the
complex syndrome of heart failure [1]. Usually it represents a late
stage of heart failure characterized by high morbidity and mortality,
hemodynamical and neurohormonal derangement and frequent hospi-
talizations. Patients with AdHF often need some sort of inotropic
support [2]. Evidence is lacking, however, on the long term prognosis
of such therapies [3]. It was recently proposed that levosimendan, an
inodilator with a unique mechanism of action [4], could offer to AdHF
patients both a hemodynamic improvement and a long term beneﬁt
[5]. Levosimendan has been used in several settings [6] from the begin-
ning of the 2000, and has been described in literature as belonging to a
new category of cardiotonic agents [7].
In 2014, two independentmeta-analyseswere published on the effect
on mortality of repetitive or intermittent doses of levosimendan in ad-
vanced heart failure [5,8]. Both analyses arrived to the same conclusionsUniversity of Helsinki Central
en).
land Ltd. This is an open access articldespite the fact that the lists of included studieswere different. Those pa-
pers were commented in an editorial by De Luca [9] in which a
criticism was made regarding the studies included in the analyses.
According to De Luca, in fact, Nieminen and coworkers should not
have included the data by Nanas et al. [10] because that study was
not randomized; while Silvetti and coworkers should not have in-
cluded the data by Levin et al. [11] because that work has not been
published as a full paper several years after the data collection.
These criticisms left open the question if a treatment with repeated
or intermittent levosimendan doses is or not safe and effective for
patients with advanced heart failure (AdHF). The need for further
evidence was advocated for changing clinical practice.
Recently Comín Colet and coworkers disclosed the data of the LION-
HEART study (Levosimendan Intermittent administration in Outpatients:
effects on Natriuretic peptides in advanced chronic HEART failure —
NCT01536132), a multicenter, double-blind, randomized, parallel group,
placebo-controlled trial evaluating the efﬁcacy and safety of intravenous
administration of intermittent doses of levosimendan in outpatients
with advanced chronic heart failure [12]. In this study 69 patients were
randomized in a 2:1 ratio to receive either levosimendan or placebo
and, among other parameters, also the effects onmortalitywere reported.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Flow diagram for selection of articles.
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repeated or intermittent levosimendan treatment in advanced heart
failure, and update the meta-analysis on mortality by leaving our the
data previously criticized in the editorial by de Luca [9] and adding re-
cently published data.2. Methods
2.1. Search strategy
Pertinent studies were independently searched in CENTRAL, Google Scholar
MEDLINE/PubMed, Scopus and the Cochrane Central Register of clinical trials (updated
May 30th, 2015) by the two authors. In addition, we employed backward snowballing
(i.e., scanning of references of retrieved articles and pertinent reviews) and contacted in-
ternational experts and the manufacturer for further studies. No language restriction was
enforced.
The full PubMed search strategy [13], aimed to include any randomized study ever
performed with intermittent levosimendan intravenous administration in patients with
chronic heart failure, was: ((levosimendan OR simdax) AND (randomized controlled
trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random
allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR clinical
trial[pt] OR clinical trials[mh] OR (clinical trial[tw] OR ((singl*[tw] OR doubl*[tw] OR
trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind[tw])) OR (latin square[tw]) OR
placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR com-
parative study[tw] OR follow-up studies[mh] OR prospective studies[mh] OR crossover
studies[mh] OR control[tw] OR controls[tw] OR controlled[tw] OR prospectiv*[tw] OR
volunteer*[tw]) NOT (animal[mh] NOT human[mh]) NOT (comment[pt] OR editorial[pt]
OR meta-analysis[pt] OR practice-guideline[pt] OR review[pt]))2.2. Studies' selection
References obtained from database and literature searches were ﬁrst independently
examined at a title/abstract level by the two authors, with divergences resolved by
consensus, and then, if potentially pertinent, retrieved as complete articles. The following
inclusion criteria were used for potentially relevant studies: random allocation to treat-
ment; comparison of levosimendan vs any control; performed in chronic heart failure
patients; using intravenous repetitive administration; with no restrictions on dose or
time of administration. The exclusion criteriawere: duplicate publications either acknowl-
edged or not (in this case we referred to the article with the longest follow-up available),
non-adult studies; oral administration of levosimendan; nomortality data. Two investiga-
tors independently assessed compliance to selection criteria and selected studies for the
ﬁnal analysis, with divergences ﬁnally resolved by consensus.
2.3. Data abstraction
Baseline and outcome data were independently abstracted by the two authors, with
divergences resolved by consensus. Speciﬁcally, we extracted potential sources of signiﬁ-
cant clinical heterogeneity, such as study design, sample size, clinical setting/indication,
levosimendan bolus dose, infusion dose and duration, control treatment, and follow-up
duration, as well as mortality data. If a trial reported multiple comparisons, the control
groupwas considered as awhole in the overall analysis and single groupswere considered
separately in subset analysis. At least two separate attempts to contact original authors
weremade in cases of missing data. The primary endpoint of the present reviewwasmor-
tality at the longest follow-up available.
2.4. Internal validity and assessment of risk of bias
The internal validity and risk of bias of included trials was appraised according
to Cochrane Collaboration methods [14], with divergences resolved by consensus.
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140 S. Silvetti, M.S. Nieminen / International Journal of Cardiology 202 (2016) 138–143Publication biaswas assessed by visually inspecting funnel plots and by analytical apprais-
al based on the Begg adjusted-rank correlation test [15] and Egger's linear regression test
[16]. According to theBeggor Eggermethods for publication bias evaluation, a two-sided p
value of 0.10 or less was regarded as signiﬁcant. Sensitivity analyses were performed by
sequentially removing each study and reanalyzing the remaining dataset (producing a
new analysis for each study removed) and by analyzing data from studies with moderate
and low risk of bias.
2.5. Data analysis and synthesis
Computations were performed with Stata (Stata Statistical Software: Release 11,
College Station, TX). Hypothesis of statistical heterogeneity was tested by means of
Cochran Q test, with statistical signiﬁcance set at the two-tailed 0.10 level, whereas extent
of statistical consistency was measured with I2, deﬁned as 100% (Q− df) / Q, where Q is
Cochran's heterogeneity statistic and df the degrees of freedom. Binary outcomes from in-
dividual studieswere analyzed to compute individual and pooled risk ratio with pertinent
95% conﬁdence intervals, by means of inverse variance method and with a ﬁxed-effect
model in the case of low statistical inconsistency (I2 b 25%) or by means of
Dersimonian–Laird and with random-effect model (which better accommodates clinical
and statistical variations) in the case of moderate or high statistical inconsistency
(I2 N 25%). In addition, we computed the number needed to treat. Statistical signiﬁcance
was set at the two tailed 0.05 level for hypothesis testing. Unadjustedp values are reported
throughout. This study was performed in compliance with The Cochrane Collaboration
and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines
[17,18].
3. Results
Database searches, snowballing, and contacts with experts yielded a
total of 327 titles (Fig. 1). Excluding 309 nonpertinent titles or abstracts,
we retrieved in a complete form and assessed 18 studies according to
the selection criteria. Speciﬁcally, three studies were excluded because
levosimendan was not administered intravenously [19–21], three stud-
ies because they were not randomized [10,22,23], two studies because
data were included in a larger or previous publication [24,25], two be-
cause lacking mortality data [26,27] and one because abstract without
subsequent publication [11]. Ultimately, therefore, we identiﬁed seven
eligible randomized clinical trials for inclusion in the analysis [12,
28–33].
3.1. Studies' characteristics
The seven included trials randomized 438 patients (257 to
levosimendan and 181 to control) and are reported in Table 1. All
studies used intermittent levosimendan in patients with advanced
chronic heart failure and one [28] in chronic heart failure due to pulmo-
nary hypertension, all in a cardiological setting. The mean length of
follow-up was 8 ± 3.8 months. Clinical heterogeneity was mostly due
to control treatment and studied drug infusion as dosage, length of infu-
sion, interval and end of administration. Four studies [12,30,31,33] used
a continuous infusion without the bolus dose. The length of infusion
ranged between 6 and 24 h. The interval of administration was weekly
for one study, every 2weeks for three studies and everymonth for three
studies. Dose varied between 6 and 12 μg/kg as intravenous bolus and
between 0.1 and 0.4 μg/kg/min as a continuous infusion. The total
range of administration was between 2 and 6 months. Two of the stud-
ies were multicentered [12,33]. Study quality appraisal indicated that
the studies were of variable quality (Table 2) and that ﬁve of them
had a moderate risk of bias while two had a low risk of bias.
3.2. Patients' characteristics
All 438 enrolled patients (257 to levosimendan and 181 to control)
had an ejection fraction less than 35% and a NYHA class III or IV at
randomization.
3.3. Quantitative data synthesis
Forest plot (Fig. 2) shows that the use of levosimendan was asso-
ciated with a signiﬁcant reduction in mortality at the longest follow-up
Fig. 2. Forest plot.
Table 2
Methodological quality summary. Review authors' judgments about each methodological quality item for each included study.
Adequate
sequence
generation?
Allocation
concealment
used?
Blinding? Concurrent
therapies
similar?
Complete outcome
data addressed?
Uniform and explicit
outcome deﬁnitions?
Free of selective
outcome reporting?
Free of
other
bias?
Overall
risk of
bias?
Altenberger J [33] Yes Yes Yes Yes Yes Yes Yes Yes Low
Berger R [29] Unclear Unclear No Yes Unclear Yes Yes Yes Moderate
Bonios MJ [30] Unclear Unclear No Yes Yes Yes Yes Yes Moderate
Comin-Coléta [12] Unclear Unclear Yes Yes Unclear Yes Yes Unclear Moderate
Kleber FX [28] Yes Unclear Yes Yes Unclear Yes Yes No Moderate
Malfatto G [31] Unclear Unclear No Yes Yes Yes Yes Yes Moderate
Mavrogeni S [32] Yes Yes Unclear Yes Yes Unclear Yes Yes Low
a Study published recently as abstract only.
141S. Silvetti, M.S. Nieminen / International Journal of Cardiology 202 (2016) 138–143available [41 of 257 (16%) in the levosimendan group vs. 39 of 181
(21.5%) in the control arm, OR = 0.54 (95% CI 0.32–0.91), p for
effect = 0.02, p for heterogeneity = 0.64, I2 = 0%].
Visual inspection of funnel plot (Fig. 3) identiﬁes a skewed and
asymmetrical shape, and quantitative evaluation suggests a presence
of publication bias, Egger's test (p = 0.017) or Begg test (p = 0.072).3.4. Sensitivity analysis
The signiﬁcant reduction in mortality at the longest follow-up
available using levosimendan was conﬁrmed ﬁtting a random effect
model [OR = 0.56 (95% CI 0.33–0.96), p for effect = 0.037, p for
heterogeneity = 0.6, I2 = 0%].
The sensitivity analysis performed by sequentially removing
each study at time and reanalyzing the remaining dataset is shown
in Table 3 The signiﬁcant result is lost only by removing theMavrogeni's
trial (p = 0.1).Fig. 3. Funnel plot.4. Discussion
In AdHF the patient experiences repeated episodes of cardiac de-
compensation and frequent and prolonged hospitalization,which result
in a severely compromised quality of life [34]. Furthermore, society is
now undergoing an increased burden of AdHF due to the aging of the
population and use of improved life-prolonging treatment options
[35]. As well as being associated with substantial morbidity andmortal-
ity, the repeated hospitalization of these patients remains the main
cause for the associated signiﬁcant healthcare expenditure [36,37]. In-
deed, following each successive admission of a patient for exacerbation
of their heart failure, they will then generally leave the hospital with a
further decreased cardiac function and a thus a higher probability of
more frequent rehospitalisation and death [38].
Studied carried out over the past 15 years have indicated that con-
tinuous or intermittent infusion of parenteral dobutamine or milrinone
as an inotropic support could provide favorable effects to support the
circulation and heart function in the long-term therapy of end-stage
heart failure [39–45]. However, there were early reports that continu-
ous or intermittent use of these traditional inotropic drugs might be
associated with an increased risk of mortality [46]. Indeed, the use of
dobutamine and phosphodiesterase inhibitors was speciﬁcally investi-
gated in two focused meta-analyses by Tacon et al. [47] and by Nony
et al. [48], respectively, where continuous or intermittent use of these
traditional inotropic drugs did not show any patient beneﬁts. OverTable 3
Sensitivity analysis.
Excluded trial OR, 95% CI p value
Altenberger J [33] 0.58 [0.33, 0.99] 0.05
Berger R [29] 0.50 [0.28, 0.89] 0.02
Bonios MJ [30] 0.47 [0.26, 0.87] 0.02
Comin-Colét [12] 0.47 [0.26, 0.87] 0.02
Kleber FX [28] 0.56 [0.33, 0.95] 0.03
Malfatto G [31] 0.56 [0.32, 0.97] 0.04
Mavrogeni S [32] 0.62 [0.35, 1.09] 0.1
All included trials 0.54 [0.32, 0.91] 0.02
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available for the treatment of acutely decompensated heart failure [4].
Levosimendan was shown to combine positive inotropic, vasodilatory,
and cardioprotective effects without any increase in the oxygen con-
sumption of myocardial tissue (for a recent review see [6]). This has
also led to several independent reports of meta-analyses on the clinical
data for levosimendan with positive indications of the advantages of
levosimendan in cardiology settings [49–51]. Very recently, a series of
case reports were published [52] in which pulsed levosimendan
therapy is described as a viable solution in patients with heart dis-
ease, at the stage where all surgical, device and traditional therapeu-
tic options have been exhausted. We cite, for the sake of completeness,
a meta-analysis — which we found in literature after our manuscript
wasﬁnalized— by Yi et al. [53] inwhich the authors conclude that inter-
mittent or repetitive levosimendan infusionmight be a promising strat-
egy to reduce mortality and improve LVEF in patients with advanced
chronic, but not necessarily acutely decompensated, heart failure to
maintain disease stability. Finally, a recent consensus paper reviewed
the beneﬁcial effects of levosimendan on Quality of Life in AdHF
patients, and suggested that treatment strategies at this stage should
be planned taking into account the ‘patient perspective’ [34].
The present meta-analysis gives a clear signal (p for effect = 0.02)
on the effect of repeated treatment with levosimendan on mortality in
patients with AdHF and low EF (≤35%) on an average follow-up period
of 8 ± 3.8 months. The heterogeneity of the results in the seven studies
is low (p for heterogeneity=0.6), but a sign of possible bias is shown by
the Begg's test of the data (p = 0.072). The latter sign, however, has to
be interpreted with caution since our meta-analysis is small, and Begg's
test is fairly powerful only for large meta-analyses [15].
5. Conclusion
The present updated meta-analysis supports the hypothesis that
repetitive or intermittent levosimendan administration for patients
with advanced heart failure is associated with reduction in mortality.
There is therefore a strong rationale for a randomized clinical trial to
be designed and carried out that has adequate power to investigate
patient mortality.
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